ABCG2 and leukemia: In addition to MAPKs, a breast cancer resistance protein (BCRP/ABCG2) was reported to be overexpressed by stem cells in leukemias, potentially contributing to their resistance to eradication by chemotherapy or targeted therapies and to be associated with a poor response to conventional chemotherapy and increased risk of relapse [43].